State Street Corp Purchases 45,529 Shares of MediWound Ltd. (NASDAQ:MDWD)

State Street Corp grew its holdings in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 219.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 66,258 shares of the biopharmaceutical company's stock after purchasing an additional 45,529 shares during the period. State Street Corp owned approximately 0.61% of MediWound worth $1,197,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of MDWD. Point72 Asset Management L.P. purchased a new stake in shares of MediWound during the third quarter worth $212,000. Investor AB purchased a new stake in MediWound during the 3rd quarter worth about $15,750,000. MetLife Investment Management LLC purchased a new stake in MediWound during the 3rd quarter worth about $89,000. ARK Investment Management LLC bought a new position in MediWound in the 3rd quarter worth about $1,806,000. Finally, Rosalind Advisors Inc. grew its holdings in MediWound by 22.3% during the 3rd quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company's stock valued at $11,343,000 after buying an additional 114,560 shares in the last quarter. 46.83% of the stock is owned by institutional investors.

MediWound Stock Down 0.1 %

NASDAQ:MDWD traded down $0.01 during trading hours on Friday, hitting $17.99. 58,226 shares of the company's stock traded hands, compared to its average volume of 66,363. The firm has a market cap of $194.04 million, a P/E ratio of -6.20 and a beta of 0.80. The business's fifty day simple moving average is $17.37 and its two-hundred day simple moving average is $17.53. MediWound Ltd. has a 52 week low of $10.95 and a 52 week high of $24.00.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the prior year, the company posted ($0.24) EPS. On average, analysts expect that MediWound Ltd. will post -2.6 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered their price target on shares of MediWound from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, November 27th.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.